Literature DB >> 23267793

Urine neutrophil gelatinase-associated lipocalin predicts graft outcome up to 1 year after kidney transplantation.

H M Choi1, K T Park, J W Lee, E Cho, S K Jo, W Y Cho, H K Kim.   

Abstract

BACKGROUND: Several recent reports demonstrated the usefulness of new biomarkers in early prediction of delayed graft function (DGF) and graft recovery after kidney transplantation (KT). It is unknown, however, whether these biomarkers would predict long-term graft outcome. In this study, we examined whether the biomarkers including neutrophil gelatinase-associated lipocalin (NGAL) and liver-type fatty acid-binding protein (L-FABP) can predict 1-year graft outcome as well as short-term graft function especially in patients with early graft function (EGF).
METHODS: This was a single-center, prospective observational study. Urine samples at 0 hours and 2 and 6 days were obtained and the level of NGAL and L-FABP were measured.
RESULTS: Of the 69 KT recipients enrolled, seven developed DGF, and the remaining 62 patients were finally enrolled as EGF recipients. EGF recipients were additionally divided into immediate graft function (IGF, n = 48) and slow graft function (SGF, n = 14) groups. Urinary NGAL (u-NGAL) level on day 2, but not L-FABP nor serum creatinine, was significantly higher in SGF compared to IGF group. Higher day 2 u-NGAL level was associated with more frequent development of SGF and, in addition, with significantly lower 1-year estimated glomerular filtration rate (eGFR). In multivariate logistic regression analysis, day 2 u-NGAL was a significant, independent factor for predicting poor long-term graft function (1-year eGFR < 60 mL/min/1.73 m(2)).
CONCLUSIONS: This study demonstrates the possibility that u-NGAL might be useful in predicting adverse 1-year outcome as well as short-term graft function even in EGF patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23267793     DOI: 10.1016/j.transproceed.2012.05.080

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Use of a Targeted Urine Proteome Assay (TUPA) to identify protein biomarkers of delayed recovery after kidney transplant.

Authors:  Kenneth R Williams; Christopher M Colangelo; Lin Hou; Lisa Chung; Justin M Belcher; Thomas Abbott; Isaac E Hall; Hongyu Zhao; Lloyd G Cantley; Chirag R Parikh
Journal:  Proteomics Clin Appl       Date:  2017-03-31       Impact factor: 3.494

Review 2.  The Most Promising Biomarkers of Allogeneic Kidney Transplant Rejection.

Authors:  Karolina Rogulska; Iwona Wojciechowska-Koszko; Barbara Dołęgowska; Ewa Kwiatkowska; Paulina Roszkowska; Patrycja Kapczuk; Danuta Kosik-Bogacka
Journal:  J Immunol Res       Date:  2022-05-28       Impact factor: 4.493

Review 3.  The Promise of Systems Biology for Diabetic Kidney Disease.

Authors:  Frank C Brosius; Wenjun Ju
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

4.  Fascin-1 is released from proximal tubular cells in response to calcineurin inhibitors (CNIs) and correlates with isometric vacuolization in kidney transplanted patients.

Authors:  Conxita Jacobs-Cachá; Irina B Torres; Joan López-Hellín; Carme Cantarell; María A Azancot; Antonio Román; Francesc Moreso; Daniel Serón; Anna Meseguer; Eduard Sarró
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

5.  Plasma Neutrophil Gelatinase-Associated Lipocalin as a Marker for Prediction of 3-Month Graft Survival after Kidney Transplantation.

Authors:  A Jafari; M R Khatami; S Dashti-Khavidaki; M Lessan-Pezeshki; A Abdollahi
Journal:  Int J Organ Transplant Med       Date:  2017-02-01

Review 6.  Neutrophil Gelatinase-Associated Lipocalin as a Biomarker of Allograft Function After Renal Transplantation: Evaluation of the Current Status and Future Insights.

Authors:  Maria Cappuccilli; Irene Capelli; Giorgia Comai; Giuseppe Cianciolo; Gaetano La Manna
Journal:  Artif Organs       Date:  2017-12-20       Impact factor: 3.094

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.